Venture capital investment in the global biotechnology industry hit $2.1 billion in the first quarter of 2007, according to data from BioWorld Financial Watch and BioWorld Snapshots. That's almost double the $1.2 billion raised in the first quarter of 2006 and a sharp spike up from the steady $1.3 billion raised in each of the second, third and fourth quarters last year. (BioWorld Today)
Neuromed Pharmaceuticals' rationale for paying $30 million up front plus milestones and royalties to Johnson & Johnson subsidiary ALZA Corp. in exchange for U.S. rights to OROS Hydromorphone might not be intuitively obvious. (BioWorld Today)
Neuromed Pharmaceuticals' rationale for paying $30 million up front plus milestones and royalties to Johnson & Johnson subsidiary ALZA Corp. in exchange for U.S. rights to OROS Hydromorphone might not be intuitively obvious. (BioWorld Today)
